233 related articles for article (PubMed ID: 37439808)
1. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J; Migliaccio AR; Kosiorek H; Bhave R; Palmer J; Kuykendall A; Mesa R; Rampal RK; Gerds AT; Yacoub A; Pettit K; Talpaz M; Komrokji R; Kremyanskaya M; Gonzalez A; Fabris F; Johnson K; Dougherty M; McGovern E; Arango Ossa J; Domenico D; Farnoud N; Weinberg RS; Kong A; Najfeld V; Vannucchi AM; Arciprete F; Zingariello M; Falchi M; Salama ME; Mead-Harvey C; Dueck A; Varricchio L; Hoffman R
Clin Cancer Res; 2023 Sep; 29(18):3622-3632. PubMed ID: 37439808
[TBL] [Abstract][Full Text] [Related]
2. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
[TBL] [Abstract][Full Text] [Related]
3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
4. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
Tibes R; Mesa RA
J Hematol Oncol; 2014 Mar; 7():18. PubMed ID: 24598114
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
7. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for myelofibrosis.
Atallah E; Verstovsek S
Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.
Tremblay D; Baine I; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1067-e1074. PubMed ID: 36117043
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
13. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
Mascarenhas J
Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
15. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
17. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL; Swords R; Hochhaus A; Giles F
Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
19. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
Mascarenhas J
Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
[TBL] [Abstract][Full Text] [Related]
20. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]